Improved Quality of the Treatment and Increased Compliance in Asthmatics Through the Dialog Tool Soren - Between Patient and Caregiver

This study has been completed.
Sponsor:
Information provided by:
AstraZeneca
ClinicalTrials.gov Identifier:
NCT00272727
First received: January 4, 2006
Last updated: January 21, 2011
Last verified: January 2011
  Purpose

The purpose of the study is to assess if a dialog tool can improve compliance and asthma control in patients with asthma.


Condition Intervention
Asthma
Behavioral: Dialog tool for caregivers

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Crossover Assignment
Masking: Open Label
Official Title: Improved Quality of the Treatment and Increased Compliance in Asthmatics Through the Dialog Tool Soren - Between Patient and Caregiver

Resource links provided by NLM:


Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • ACQ

Secondary Outcome Measures:
  • Ability to follow prescription, AQLQ, lung function, No, eosinophil

Estimated Enrollment: 100
Study Start Date: February 2006
Study Completion Date: May 2007
  Eligibility

Ages Eligible for Study:   18 Years to 40 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Diagnosis of asthma >/= 3 months,
  • Prescribed daily use of inhaled glucocorticosteroid

Exclusion Criteria:

  • Asthma exacerbation within the last month
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00272727

Locations
Denmark
Research Site
Copenhagen, Denmark
Sponsors and Collaborators
AstraZeneca
Investigators
Study Director: AstraZeneca Denmark Medical Director, MD AstraZeneca
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00272727     History of Changes
Other Study ID Numbers: NIS-RDK-DUM-2005/1, AZ-SOREN
Study First Received: January 4, 2006
Last Updated: January 21, 2011
Health Authority: Denmark: Danish Medicines Agency

Keywords provided by AstraZeneca:
Asthma
dialog tool
compliance

Additional relevant MeSH terms:
Asthma
Bronchial Diseases
Respiratory Tract Diseases
Lung Diseases, Obstructive
Lung Diseases
Respiratory Hypersensitivity
Hypersensitivity, Immediate
Hypersensitivity
Immune System Diseases

ClinicalTrials.gov processed this record on July 23, 2014